As antibiotic resistant bacteria threaten a public health crisis, biotechnology is turning to bacteriophages, nature's tiniest viruses. But can phage therapy overcome its historical baggage?
This is a preview of subscription content, log in via an institution to check access.
R. Henretta
References
US Centers for Disease Control, the Food and Drug Administration and the US National Institutes of Health. A Public Health Action Plan to Combat Antimicrobial Resistance (CDC, FDA & NIH, June, 2000) (http://www.cdc.gov/drugresistance/ actionplan/aractionplan.pdf).
S. Tslodras et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207–208 (2001).
G.M. Eliopoulos, et al. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin. Antimicrobial Agents Chemother. 42, 1088–1092 (1998).
Fox, J. Concerns raised over declining antiinfective R&D. Nat. Biotechnol. 21, 1255–1256 (2003).
Scholl, D. et al. Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli. J. Virol. 75, 2509–2515 (2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thiel, K. Old dogma, new tricks—21st Century phage therapy. Nat Biotechnol 22, 31–36 (2004). https://doi.org/10.1038/nbt0104-31
Issue Date:
DOI: https://doi.org/10.1038/nbt0104-31
- Springer Nature America, Inc.
This article is cited by
-
Characterization of selected phages for biocontrol of food-spoilage pseudomonads
International Microbiology (2024)
-
Isolation and characterization of a novel bacteriophage infecting Vibrio alginolyticus
Archives of Microbiology (2018)
-
Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages
Scientific Reports (2017)